Analysis of Postvaccination Breakthrough COVID-19 Infections Among Adults With HIV in the United States | HIV | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Analysis of Postvaccination Breakthrough COVID-19 Infections Among Adults With HIV in the United States

Educational Objective
To identify the key insights or developments described in this article
1 Credit CME
Key Points

Question  Are the rate and risk of COVID-19 breakthrough infections higher among vaccinated people with vs without HIV in the United States through December 31, 2021?

Findings  In this cohort study of 113 994 patients, risk of breakthrough infection was low overall (3.8%) but 28% higher in people with vs without HIV. The breakthrough rate was also higher in people with vs without HIV (55 cases per 1000 person-years vs 43 cases per 1000 person-years).

Meaning  The higher rate and risk of infection in people with HIV observed in this study suggests comprehensive inclusion of this population in recommendations for additional primary doses in immunocompromised groups.

Abstract

Importance  Recommendations for additional doses of COVID-19 vaccines for people with HIV (PWH) are restricted to those with advanced disease or unsuppressed HIV viral load. Understanding SARS-CoV-2 infection risk after vaccination among PWH is essential for informing vaccination guidelines.

Objective  To estimate the rate and risk of breakthrough infections among fully vaccinated PWH and people without HIV (PWoH) in the United States.

Design, Setting, and Participants  This cohort study used the Corona-Infectious-Virus Epidemiology Team (CIVET)-II (of the North American AIDS Cohort Collaboration on Research and Design [NA-ACCORD], which is part of the International Epidemiology Databases to Evaluate AIDS [IeDEA]), collaboration of 4 prospective, electronic health record–based cohorts from integrated health systems and academic health centers. Adult PWH who were fully vaccinated prior to June 30, 2021, were matched with PWoH on date of full vaccination, age, race and ethnicity, and sex and followed up through December 31, 2021.

Exposures  HIV infection.

Main Outcomes and Measures  COVID-19 breakthrough infections, defined as laboratory evidence of SARS-CoV-2 infection or COVID-19 diagnosis after a patient was fully vaccinated.

Results  Among 113 994 patients (33 029 PWH and 80 965 PWoH), most were 55 years or older (80 017 [70%]) and male (104 967 [92%]); 47 098 (41%) were non-Hispanic Black, and 43 218 (38%) were non-Hispanic White. The rate of breakthrough infections was higher in PWH vs PWoH (55 [95% CI, 52-58] cases per 1000 person-years vs 43 [95% CI, 42-45] cases per 1000 person-years). Cumulative incidence of breakthroughs 9 months after full vaccination was low (3.8% [95% CI, 3.7%-3.9%]), albeit higher in PWH vs PWoH (4.4% vs 3.5%; log-rank P < .001; risk difference, 0.9% [95% CI, 0.6%-1.2%]) and within each vaccine type. Breakthrough infection risk was 28% higher in PWH vs PWoH (adjusted hazard ratio, 1.28 [95% CI, 1.19-1.37]). Among PWH, younger age (<45 y vs 45-54 y), history of COVID-19, and not receiving an additional dose (aHR, 0.71 [95% CI, 0.58-0.88]) were associated with increased risk of breakthrough infections. There was no association of breakthrough with HIV viral load suppression, but high CD4 count (ie, ≥500 cells/mm3) was associated with fewer breakthroughs among PWH.

Conclusions and Relevance  In this study, COVID-19 vaccination, especially with an additional dose, was effective against infection with SARS-CoV-2 strains circulating through December 31, 2021. PWH had an increased risk of breakthrough infections compared with PWoH. Expansion of recommendations for additional vaccine doses to all PWH should be considered.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Accepted for Publication: April 21, 2022.

Published: June 7, 2022. doi:10.1001/jamanetworkopen.2022.15934

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Coburn SB et al. JAMA Network Open.

Corresponding Author: Keri N. Althoff, PhD, MPH, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St, Rm E7142, Baltimore, MD 20295 (kalthoff@jhu.edu).

Author Contributions: Dr Althoff and Mrs Humes had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Coburn, Lang, Stewart, Napravnik, Park, Justice, Gordon, Horberg, Certa, Skarbinski, Williams, Althoff.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Coburn, Lang, Napravnik, Certa, Althoff.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Coburn, Humes, Lang, Stewart, Napravnik, Edwards, Althoff.

Obtained funding: Napravnik, Justice, Althoff.

Administrative, technical, or material support: Stewart, Hogan, Gebo, Napravnik, Edwards, Browne, Park, Justice, Horberg, Certa, Watson, Jefferson, Skarbinski, Leyden, Williams.

Supervision: Napravnik, Justice, Althoff.

Conflict of Interest Disclosures: Dr Lang reported receiving grants from the Canadian Institutes of Health Research, Alberta Innovates, and Cumming School of Medicine, University of Calgary/Alberta Health Services outside the submitted work and receiving a postdoctoral fellowship supported by a Helios UCMG Post fellowship award from the University of Calgary Cumming School of Medicine as well as a Dr Subrata Ghosh Fellowship Award from the Department of Medicine, University of Calgary. Dr Gebo reported receiving grants from the Department of Defense (paid to institution) outside the submitted work. Dr Edwards reported receiving grants from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Disease (NIAID) outside the submitted work. Dr Justice reported receiving grants from NIH outside the submitted work. Dr Certa reported receiving grants from NIAID outside the submitted work. Dr Althoff reported serving as a consultant to the All of Us Research Program (NIH), TrioHealth, Kennedy Dundas, and MedIQ outside the submitted work. No other disclosures were reported.

Funding/Support: This project was funded via supplemental funds to the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD, U01AI069918) from NIAID. The NA-ACCORD is supported by NIH grants U01AI069918, F31AI124794, F31DA037788, G12MD007583, K01AI093197, K01AI131895, K23EY013707, K24AI065298, K24AI118591, K24DA000432, KL2TR000421, N01CP01004, N02CP055504, N02CP91027, P30AI027757, P30AI027763, P30AI027767, P30AI036219, P30AI050409, P30AI050410, P30AI094189, P30AI110527, P30MH62246, R01AA016893, R01DA011602, R01DA012568, R01AG053100, R24AI067039, R34DA045592, U01AA013566, U01AA020790, U01AI038855, U01AI038858, U01AI068634, U01AI068636, U01AI069432, U01AI069434, U01DA036297, U01DA036935, U10EY008057, U10EY008052, U10EY008067, U01HL146192, U01HL146193, U01HL146194, U01HL146201, U01HL146202, U01HL146203, U01HL146204, U01HL146205, U01HL146208, U01HL146240, U01HL146241, U01HL146242, U01HL146245, U01HL146333, U24AA020794, U54GM133807, UL1RR024131, UL1TR000004, UL1TR000083, UL1TR002378, U24-AA020794, U01-AA020790, U24-AA022001, U10 AA013566-completed, UL1-TR002489, Z01CP010214, and Z01CP010176; contracts CDC-200-2006-18797 and CDC-200-2015-63931 from the US Centers for Disease Control and Prevention; contract 90047713 from the Agency for Healthcare Research and Quality; contract 90051652 from the Health Resources and Services Administration; the Grady Health System; grants CBR-86906, CBR-94036, HCP-97105, and TGF-96118 from the Canadian Institutes of Health Research; the Ontario Ministry of Health and Long-term Care; and the Government of Alberta, Canada. Additional support was provided by NIAID; the National Cancer Institute; the National Heart, Lung, and Blood Institute; the Eunice Kennedy Shriver National Institute of Child Health & Human Development; National Human Genome Research Institute; National Institute for Mental Health; National Institute on Drug Abuse; National Institute on Aging; National Institute Of Dental & Craniofacial Research; National Institute of Neurological Disorders And Stroke; National Institute of Nursing Research; National Institute on Alcohol Abuse and Alcoholism; National Institute on Deafness and Other Communication Disorders; and National Institute of Diabetes and Digestive and Kidney Diseases.

Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Group Information: For the Corona-Infectious-Virus Epidemiology Team (CIVETs) of the NA-ACCORD of IeDEA (International Epidemiology Databases to Evaluate AIDS).

Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the US Centers for Disease Control and Prevention.

References
1.
Polack  FP , Thomas  SJ , Kitchin  N ,  et al; C4591001 Clinical Trial Group.  Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine.   N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577PubMedGoogle ScholarCrossref
2.
Baden  LR , El Sahly  HM , Essink  B ,  et al; COVE Study Group.  Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine.   N Engl J Med. 2021;384(5):403-416. doi:10.1056/NEJMoa2035389PubMedGoogle ScholarCrossref
3.
Sadoff  J , Gray  G , Vandebosch  A ,  et al; ENSEMBLE Study Group.  Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19.   N Engl J Med. 2021;384(23):2187-2201. doi:10.1056/NEJMoa2101544PubMedGoogle ScholarCrossref
4.
Birhane  M , Bressler  S , Chang  G ,  et al; CDC COVID-19 Vaccine Breakthrough Case Investigations Team.  COVID-19 vaccine breakthrough infections reported to CDC—United States, January 1-April 30, 2021.   MMWR Morb Mortal Wkly Rep. 2021;70(21):792-793. doi:10.15585/mmwr.mm7021e3PubMedGoogle ScholarCrossref
5.
Teran  RA , Walblay  KA , Shane  EL ,  et al.  Postvaccination SARS-CoV-2 infections among skilled nursing facility residents and staff members—Chicago, Illinois, December 2020-March 2021.   Am J Transplant. 2021;21(6):2290-2297. doi:10.1111/ajt.16634PubMedGoogle ScholarCrossref
6.
Butt  AA , Yan  P , Shaikh  OS , Mayr  FB .  Outcomes among patients with breakthrough SARS-CoV-2 infection after vaccination in a high-risk national population.   EClinicalMedicine. 2021;40:101117. doi:10.1016/j.eclinm.2021.101117PubMedGoogle ScholarCrossref
7.
Hacisuleyman  E , Hale  C , Saito  Y ,  et al.  Vaccine breakthrough infections with SARS-CoV-2 variants.   N Engl J Med. 2021;384(23):2212-2218. doi:10.1056/NEJMoa2105000PubMedGoogle ScholarCrossref
8.
Thompson  MG , Burgess  JL , Naleway  AL ,  et al.  Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers—eight U.S. locations, December 2020-March 2021.   MMWR Morb Mortal Wkly Rep. 2021;70(13):495-500. doi:10.15585/mmwr.mm7013e3PubMedGoogle ScholarCrossref
9.
Tang  L , Hijano  DR , Gaur  AH ,  et al.  Asymptomatic and symptomatic SARS-CoV-2 infections after BNT162b2 vaccination in a routinely screened workforce.   JAMA. 2021;325(24):2500-2502. doi:10.1001/jama.2021.6564PubMedGoogle ScholarCrossref
10.
Liu  C , Lee  J , Ta  C ,  et al.  A retrospective analysis of COVID-19 mRNA vaccine breakthrough infections—risk factors and vaccine effectiveness.   medRxiv. Preprint posted online October 7, 2021. doi:10.1101/2021.10.05.21264583Google Scholar
11.
Butt  AA , Khan  T , Yan  P , Shaikh  OS , Omer  SB , Mayr  F .  Rate and risk factors for breakthrough SARS-CoV-2 infection after vaccination.   J Infect. 2021;83(2):237-279. doi:10.1016/j.jinf.2021.05.021PubMedGoogle ScholarCrossref
12.
Sun  J , Zheng  Q , Madhira  V ,  et al; National COVID Cohort Collaborative (N3C) Consortium.  Association between immune dysfunction and COVID-19 breakthrough infection after SARS-CoV-2 vaccination in the US.   JAMA Intern Med. 2022;182(2):153-162. doi:10.1001/jamainternmed.2021.7024PubMedGoogle ScholarCrossref
13.
Centers for Disease Control and Prevention. COVID-19 vaccines for moderately to severely immunocompromised people. Accessed October 28, 2021. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html
14.
Deeks  SG .  HIV infection, inflammation, immunosenescence, and aging.   Annu Rev Med. 2011;62:141-155. doi:10.1146/annurev-med-042909-093756PubMedGoogle ScholarCrossref
15.
Gange  SJ , Kitahata  MM , Saag  MS ,  et al.  Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD).   Int J Epidemiol. 2007;36(2):294-301. doi:10.1093/ije/dyl286PubMedGoogle ScholarCrossref
16.
Centers for Disease Control and Prevention. When you’ve been fully vaccinated. Accessed November 4, 2021. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/fully-vaccinated.html
17.
Fultz  SL , Skanderson  M , Mole  LA ,  et al.  Development and verification of a “virtual” cohort using the National VA Health Information System.   Med Care. 2006;44(8)(suppl 2):S25-S30. doi:10.1097/01.mlr.0000223670.00890.74PubMedGoogle ScholarCrossref
18.
Centers for Disease Control and Prevention. AIDS-defining conditions: MMWR recommendations and reports. Published December 5, 2008. Accessed November 17, 2021. https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5710a2.htm
19.
Malinis  M , Cohen  E , Azar  MM .  Effectiveness of SARS-CoV-2 vaccination in fully vaccinated solid organ transplant recipients.   Am J Transplant. 2021;21(8):2916-2918. doi:10.1111/ajt.16713PubMedGoogle ScholarCrossref
20.
Anjan  S , Natori  Y , Fernandez Betances  AA ,  et al.  Breakthrough COVID-19 infections after mRNA vaccination in solid organ transplant recipients in Miami, Florida.   Transplantation. 2021;105(10):e139-e141. doi:10.1097/TP.0000000000003902PubMedGoogle ScholarCrossref
21.
Becerril-Gaitan  A , Vaca-Cartagena  BF , Ferrigno  AS ,  et al.  Immunogenicity and risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection after coronavirus disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis.   Eur J Cancer. 2022;160:243-260. doi:10.1016/j.ejca.2021.10.014PubMedGoogle ScholarCrossref
22.
Tenforde  MW , Patel  MM , Ginde  AA ,  et al; Influenza and Other Viruses in the Acutely Ill (IVY) Network.  Effectiveness of SARS-CoV-2 mRNA vaccines for preventing COVID-19 hospitalizations in the United States.   Clin Infect Dis. 2021;(August):ciab687. doi:10.1093/cid/ciab687PubMedGoogle ScholarCrossref
23.
Cohn  BA , Cirillo  PM , Murphy  CC , Krigbaum  NY , Wallace  AW .  SARS-CoV-2 vaccine protection and deaths among US veterans during 2021.   Science. 2022;375(6578):331-336. doi:10.1126/science.abm0620PubMedGoogle ScholarCrossref
24.
Wang  L , Wang  QQ , Davis  PB , Volkow  ND , Xu  R .  Increased risk for COVID-19 breakthrough infection in fully vaccinated patients with substance use disorders in the United States between December 2020 and August 2021.   World Psychiatry. 2022;21(1):124-132. doi:10.1002/wps.20921PubMedGoogle ScholarCrossref
25.
Margraf  J , Brailovskaia  J , Schneider  S .  Behavioral measures to fight COVID-19: an 8-country study of perceived usefulness, adherence and their predictors.   PLoS One. 2020;15(12):e0243523. doi:10.1371/journal.pone.0243523PubMedGoogle ScholarCrossref
26.
Lu  P , Kong  D , Shelley  M .  Risk perception, preventive behavior, and medical care avoidance among American older adults during the COVID-19 pandemic.   J Aging Health. 2021;33(7-8):577-584. doi:10.1177/08982643211002084PubMedGoogle ScholarCrossref
27.
CDC COVID Data Tracker. COVID-19 weekly cases and deaths per 100,000 population by age, race/ethnicity, and sex. Accessed November 6, 2021. https://covid.cdc.gov/covid-data-tracker/#demographicsovertime
28.
Yang  X , Sun  J , Patel  RC ,  et al; National COVID Cohort Collaborative Consortium.  Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data.   Lancet HIV. 2021;8(11):e690-e700. doi:10.1016/S2352-3018(21)00239-3PubMedGoogle ScholarCrossref
29.
Tesoriero  JM , Swain  CE , Pierce  JL ,  et al.  COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York State.   JAMA Netw Open. 2021;4(2):e2037069. doi:10.1001/jamanetworkopen.2020.37069PubMedGoogle ScholarCrossref
30.
Yousaf  M , Hameed  M , Alsoub  H , Khatib  M , Jamal  W , Ahmad  M .  COVID-19: prolonged viral shedding in an HIV patient with literature review of risk factors for prolonged viral shedding and its implications for isolation strategies.   Clin Case Rep. 2021;9(3):1397-1401. doi:10.1002/ccr3.3786PubMedGoogle ScholarCrossref
31.
Corsini Campioli  C , Cano Cevallos  E , Assi  M , Patel  R , Binnicker  MJ , O’Horo  JC .  Clinical predictors and timing of cessation of viral RNA shedding in patients with COVID-19.   J Clin Virol. 2020;130:104577. doi:10.1016/j.jcv.2020.104577PubMedGoogle ScholarCrossref
32.
Li  TZ , Cao  ZH , Chen  Y ,  et al.  Duration of SARS-CoV-2 RNA shedding and factors associated with prolonged viral shedding in patients with COVID-19.   J Med Virol. 2021;93(1):506-512. doi:10.1002/jmv.26280PubMedGoogle ScholarCrossref
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close